Cargando…

Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy

Cancer stem cells (CSC), also termed “cancer initiating cells” or “cancer progenitor cells”, which have the ability to self-renew, proliferate, and maintain the neoplastic clone, have recently been discovered in a wide variety of pediatric tumors. These CSC are thought to be responsible for tumorige...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedman, Gregory K., Cassady, Kevin A., Beierle, Elizabeth A., Markert, James M., Gillespie, G. Yancey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607376/
https://www.ncbi.nlm.nih.gov/pubmed/22430386
http://dx.doi.org/10.1038/pr.2011.58
_version_ 1782264104754348032
author Friedman, Gregory K.
Cassady, Kevin A.
Beierle, Elizabeth A.
Markert, James M.
Gillespie, G. Yancey
author_facet Friedman, Gregory K.
Cassady, Kevin A.
Beierle, Elizabeth A.
Markert, James M.
Gillespie, G. Yancey
author_sort Friedman, Gregory K.
collection PubMed
description Cancer stem cells (CSC), also termed “cancer initiating cells” or “cancer progenitor cells”, which have the ability to self-renew, proliferate, and maintain the neoplastic clone, have recently been discovered in a wide variety of pediatric tumors. These CSC are thought to be responsible for tumorigenesis, tumor maintenance, aggressiveness and recurrence due to inherent resistance to current treatment modalities such as chemotherapy and radiation. Oncolytic virotherapy offers a novel, targeted approach for eradicating pediatric CSC by utilizing mechanisms of cell killing that differ from conventional therapies. Moreover, oncolytic viruses have the ability to target specific features of CSC such as cell surface proteins, transcription factors, and the CSC microenvironment. Through genetic engineering, a wide variety of foreign genes may be expressed by oncolytic viruses to augment the oncolytic effect. We review the current data regarding the ability of several types of oncolytic viruses (herpes simplex virus-1 (HSV-1), adenovirus, reovirus, Seneca Valley virus, vaccinia virus, Newcastle disease virus, myxoma virus, vesicular stomatitis virus) to target and kill both CSC and tumor cells in pediatric tumors. We highlight advantages and limitations of each virus and potential ways next-generation engineered viruses may target resilient CSC.
format Online
Article
Text
id pubmed-3607376
institution National Center for Biotechnology Information
language English
publishDate 2012
record_format MEDLINE/PubMed
spelling pubmed-36073762013-03-25 Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy Friedman, Gregory K. Cassady, Kevin A. Beierle, Elizabeth A. Markert, James M. Gillespie, G. Yancey Pediatr Res Article Cancer stem cells (CSC), also termed “cancer initiating cells” or “cancer progenitor cells”, which have the ability to self-renew, proliferate, and maintain the neoplastic clone, have recently been discovered in a wide variety of pediatric tumors. These CSC are thought to be responsible for tumorigenesis, tumor maintenance, aggressiveness and recurrence due to inherent resistance to current treatment modalities such as chemotherapy and radiation. Oncolytic virotherapy offers a novel, targeted approach for eradicating pediatric CSC by utilizing mechanisms of cell killing that differ from conventional therapies. Moreover, oncolytic viruses have the ability to target specific features of CSC such as cell surface proteins, transcription factors, and the CSC microenvironment. Through genetic engineering, a wide variety of foreign genes may be expressed by oncolytic viruses to augment the oncolytic effect. We review the current data regarding the ability of several types of oncolytic viruses (herpes simplex virus-1 (HSV-1), adenovirus, reovirus, Seneca Valley virus, vaccinia virus, Newcastle disease virus, myxoma virus, vesicular stomatitis virus) to target and kill both CSC and tumor cells in pediatric tumors. We highlight advantages and limitations of each virus and potential ways next-generation engineered viruses may target resilient CSC. 2012-02-15 2012-04 /pmc/articles/PMC3607376/ /pubmed/22430386 http://dx.doi.org/10.1038/pr.2011.58 Text en Users may view, print, copy, download and text and data- mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Friedman, Gregory K.
Cassady, Kevin A.
Beierle, Elizabeth A.
Markert, James M.
Gillespie, G. Yancey
Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
title Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
title_full Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
title_fullStr Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
title_full_unstemmed Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
title_short Targeting Pediatric Cancer Stem Cells with Oncolytic Virotherapy
title_sort targeting pediatric cancer stem cells with oncolytic virotherapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3607376/
https://www.ncbi.nlm.nih.gov/pubmed/22430386
http://dx.doi.org/10.1038/pr.2011.58
work_keys_str_mv AT friedmangregoryk targetingpediatriccancerstemcellswithoncolyticvirotherapy
AT cassadykevina targetingpediatriccancerstemcellswithoncolyticvirotherapy
AT beierleelizabetha targetingpediatriccancerstemcellswithoncolyticvirotherapy
AT markertjamesm targetingpediatriccancerstemcellswithoncolyticvirotherapy
AT gillespiegyancey targetingpediatriccancerstemcellswithoncolyticvirotherapy